 Galera Therapeutics, Inc. GRTX, a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a retrospective analysis of Phase 2b trial data demonstrating the potential renal protective activity of lead candidate avasopasem manganese GC4419, and two ongoing clinical trials evaluating avasopasem, will be presented at the American Society of Clinical Oncology ASCO 2020 Virtual Scientific Program, taking place May 29-31, 2020. We look forward to sharing important clinical updates that underscore the potential of avasopasem to address radiation-induced toxicities and enhance the anti-cancer efficacy of chemoradiotherapy, said Mel Sorensen, M.D., President and CEO of Galera. 